Anterior Uveitis - Pipeline Insight, 2024

Anterior Uveitis - Pipeline Insight, 2024

DelveInsight’s, “Anterior Uveitis - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Anterior Uveitis: Understanding

Anterior Uveitis: Overview

Anterior uveitis (also known as iritis) is an inflammatory condition affecting the front part of the eye (around the iris). One in every three patients will have recurrent attacks. Although it usually affects one eye at time, both eyes can be affected at the same time, or one eye shortly after the other. In approximately 50% of cases, no cause can be found. In other cases it is caused by injury or infection. Some patients with anterior uveitis may also have inflammation elsewhere in the body e.g. ankylosing spondylitis, inflammatory bowel disease, and sarcoidosis. Around half of patients with anterior uveitis are born with a genetic variant known as Human Leucocyte Antigen (HLA) B27 which makes them more likely to develop the condition. Acute anterior uveitis usually comes on suddenly, producing a dull ache, redness, light intolerance and blurred vision in one eye. Symptoms of anterior uveitis may include sudden blurry vision, floaters, eye pain, red eyes, and sensitivity to light. In some cases, the symptoms may resolve on their own if they are mild, but early diagnosis and treatment are important to prevent complications and preserve vision. If left untreated, uveitis can cause permanent vision loss.

Diagnosis of anterior uveitis is based on a complete review of symptoms, an understanding of systemic diseases, and laboratory testing. A doctor of optometry will carefully examine the front and inside of the eye with a unique microscope called a slit lamp. Inflammatory cells in anterior uveitis may be seen in the anterior chamber (iritis), and sometimes the anterior vitreous (behind the lens, in iridocyclitis). Common presenting signs of acute anterior uveitis include circumlimbal injection and anterior chamber cells. Laboratory testing should be tailored to a specific diagnosis or diagnosis rather than ordering a battery of tests. If the ophthalmologist thinks an underlying condition may be the cause of uveitis, you may be referred to another doctor for a general medical examination and laboratory tests. The treatment for anterior uveitis aims to manage inflammation, relieve symptoms, and prevent complications. According to a review on the management of anterior uveitis, the general goals of medical treatment are to provide relief from pain and sensitivity to light, eliminate inflammation, prevent structural complications such as synechiae, secondary cataract, and glaucoma, and preserve or restore good visual function. The primary approach involves the use of corticosteroids, which are the drug of choice for treating anterior uveitis. Topical corticosteroids, such as eye drops, are often sufficient to achieve adequate therapeutic levels in the eye. In some cases, systemic therapy with oral corticosteroids and immunosuppressant may be necessary, especially for severe or recurrent uveitis. Additionally, prescription eye drops that dilate the pupils and reduce inflammation may be used. Surgical intervention is reserved for managing complications of uveitis, and referral to a uveitis specialist may be considered for complex cases. Early and aggressive treatment is essential to preserve vision and prevent significant morbidity associated with uveitis.

""Anterior Uveitis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anterior Uveitis pipeline landscape is provided which includes the disease overview and Anterior Uveitis treatment guidelines. The assessment part of the report embraces, in depth Anterior Uveitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anterior Uveitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anterior Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve Anterior Uveitis

Anterior Uveitis Emerging Drugs Chapters

This segment of the Anterior Uveitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anterior Uveitis Emerging Drugs

TRS01: Tarsier Pharma

Dazdotuftide (formerly known as TRS01) is a first-in-class drug with a new and unique mechanism of action, for the treatment of ocular blinding diseases of back- and front- of the eye. Dazdotuftide is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action. Dazdotuftide was found to modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macrophages (M2). Due to dazdotuftide's unique mechanism of action of immunomodulation, it has the potential to treat these debilitating diseases with a sustained effect and minimal risk of IOP elevation. Currently, the drug is Phase III stage of its clinical trial for the treatment of anterior uveitis.

Further product details are provided in the report……..

Anterior Uveitis Therapeutic Assessment

This segment of the report provides insights about the different Anterior Uveitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anterior Uveitis

There are approx. 3+ key companies which are developing the therapies for Anterior Uveitis. The companies which have their Anterior Uveitis drug candidates in the most advanced stage, i.e. Phase III include, Tarsier Pharma.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anterior Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anterior Uveitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anterior Uveitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anterior Uveitis drugs.

Anterior Uveitis Report Insights

Anterior Uveitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Anterior Uveitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Anterior Uveitis drugs?

How many Anterior Uveitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Helicobacter Pylori Infection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anterior Uveitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anterior Uveitis and their status?

What are the key designations that have been granted to the emerging drugs? 

Key Players

Tarsier Pharma

Oculis Pharma

Novaliq

Key Products

TRS01

OCS 2

Tacrolimus